Harry Welten

Harry Welten is currently the Chairman at Proteomedix AG, Director at BioSupport AG, Director at Kanyos Bio, Inc., Chief Financial Officer at Affimed NV, Member-Management Board at Horizon Therapeutics Switzerland GmbH, Member-Foundation Council at Fondation De l'Hôpital Barrie Memorial, Member-Foundation Council at HBM Fondation, and Member-Supervisory Board at Affimed GmbH.
He previously served as Chairman at Novaremed AG, Director at UBS Securities LLC, Director at Kuros Biosurgery Holding AG, Independent Director at European Medical Solutions, Director at Synosia Therapeutics, Inc., Director at BiognoSYS AG, Director at Proteomedix AG, Director at Anokion SA, Director at Kuros Biosciences Ltd., Director at Kuros Biosciences AG, Director at Virometix AG, and Member-Management Board at Synosia Therapeutics AG.
He also held the position of Chief Financial Officer & Executive Vice President at Cytos Biotechnology AG and Chief Financial Officer & Senior Vice President at Arpida AG.
Mr. Welten obtained an undergraduate degree and an MBA from The Trustees of Columbia University in The City of New York.